Celcuity Stock

Celcuity Stock-Based Compensation

The Stock-Based Compensation (SBC) of Celcuity (CELC) as of Aug 22, 2026 is 21.38 M USD. In the previous year, Stock-Based Compensation (SBC) was 6.99 M USD — a change of 206.00% (higher).

Stock-Based Compensation

21.38 MUSD

YoY

206.00%

Last updated:

Stock-Based Compensation (SBC) of Celcuity is 2026 21.38 M USD. Stock-Based Compensation (SBC) of Celcuity was 2025 6.99 M USD. It decreases by 206.00% higher compared to the previous year.

The Celcuity Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2018
1.17 M USD
Jan 1, 2019
1.04 M USD
Jan 1, 2020
1.76 M USD
Jan 1, 2021
2.61 M USD
Jan 1, 2022
4.64 M USD
Jan 1, 2023
4.90 M USD
Jan 1, 2024
6.99 M USD
Jan 1, 2025
21.38 M USD
The Celcuity Stock-Based Compensation history
YEARStock-Based CompensationYoY
21.38 MUSD+206.00%
6.99 MUSD+42.57%
4.90 MUSD+5.68%
4.64 MUSD+77.71%
2.61 MUSD+47.97%
1.76 MUSD+69.44%
1.04 MUSD-10.92%
1.17 MUSD+33.65%
874,386.00USD+366.82%
187,306.00USD+231.47%
56,507.00USD
Access this data via the Eulerpool API

Celcuity Stock analysis

What does Celcuity do? Celcuity Inc is a biotechnology company founded by Brian Sullivan in 2012. The company is headquartered in Minneapolis, USA. The business model of Celcuity is based on researching and developing new diagnostic and treatment methods for various types of cancer. The company utilizes a proprietary technology platform called CELx, which enables the analysis of cancer cell signaling pathways and the development of individualized treatment strategies. Celcuity specializes in the development of diagnostics and personalized therapies based on individual cancer cell signaling pathways. The company operates in two divisions: 1. Diagnostics division: Celcuity's diagnostics division focuses on identifying new cancer markers and biomarkers for early detection of cancer and the development of individualized treatment strategies. 2. Therapy division: Celcuity's therapy division specializes in the development of personalized therapies based on individual cancer cell signaling pathways. Celcuity currently offers two products based on the CELx technology platform: 1. CELx HUB: CELx HUB is a cloud-based software that allows doctors and researchers to analyze cancer samples and develop individualized treatment strategies. 2. CELx TIL: CELx TIL is a diagnostic tool that measures the presence of tumor cells in the immune system of cancer patients. In summary, Celcuity Inc is a leader in the field of personalized cancer therapy based on individual cancer cell signaling pathways. The company has found a niche in this growing market and has a unique technology platform that allows it to serve its customers effectively. With its products and services, Celcuity is helping to revolutionize cancer treatment and improve the quality of life for cancer patients worldwide. Celcuity is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Celcuity stock

Stock-Based Compensation (SBC) of Celcuity is 21.38 M USD in 2026.

Stock-Based Compensation (SBC) of Celcuity changed from 6.99 M USD to 21.38 M USD, representing a 206.00% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Celcuity since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Celcuity historically and in real time.

Access this data via the Eulerpool API

Cash Flow — Celcuity

All Key Metrics — Celcuity